Login
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc.

korsana.com

What Do They Do?

Develops potential anesthetic-based drug treatments for patients with treatment-resistant depression and seeks licenses for legacy drug assets.

How Do They Make Money?

The company earns money from licensing drug rights through upfront and milestone payments and royalties; it also sells development materials and collects fees for options to license drug candidates.

revenue
SegmentShareRevenue
Revenue from license agreement
Licensed

48%
Revenue from purchase agreement
Sold outright

39%
Revenue from option agreement
Licensed

13%

Who Are Their Customers?

Akebia pays directly under the praliciguat license and for development materials; a third-party optionee paid fees for an option to license olinciguat.

Do Revenues Turn Into Profits?

No. It lost $3.5M in FY2025.

Operating income, FY2025
−240% of revenue
▼ −37% (Loss) vs FY2024 (−$3.6M, −181%)
Net income, FY2025
−170% of revenue
▼ −15% (Loss) vs FY2024 (−$3.1M, −153%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −114% (Loss)
vs −$21.7M in Q3 FY2025
  • Sep 8, 2026 Korsana completed its merger with Cyclerion A private financing generated $380 million in gross proceeds before closing.

Shrinking. Revenue fell 47% in 4 years, from $3.9M in FY2021 to $2.1M in FY2025, about 15% a year.

Focus on depression treatment The older report described drug candidates for several disease areas. The latest report centers development on an anesthetic-based approach for treatment-resistant depression.

Legacy drug assets The older report presented central nervous system drug candidates as part of the development portfolio; the latest report says some legacy assets were sold, internal research on that drug class stopped, and remaining assets may be licensed.

Revenue over time
Revenue from license agreement Revenue from purchase agreement Revenue from option agreement Option to license revenue
$2.5M$1.3M$0

Who Do They Compete With?

Competes with Johnson & Johnson, Eli Lilly, AbbVie, Pfizer, Novartis, Compass Pathways, and Axsome Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support